Biotech | April 09, 2026
Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Call it a major breakthrough for diagnostic imaging
The company plans to submit the vaccine for regulatory review
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
Germany will be the first launch market
Huwel’s diagnostic solutions leverage open RT-PCR system
Subscribe To Our Newsletter & Stay Updated
